ABCELLERA BIOLOGICS INC

AbCellera insider activity: senior execs buy 111 k zero‑cost options, signaling confidence in its antibody platform—what it means for investors.

AbCellera CFO’s $0.19 buy of 250k shares signals internal confidence; investors eye short‑term momentum and future clinical milestones.

AbCellera CFO Andrew Booth’s recent share purchase signals rising insider confidence amid strong earnings, a 20% yearly gain, and growing antibody‑pipeline prospects.